Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Other Accumulated Expenses (2020 - 2025)

SAB Biotherapeutics' Other Accumulated Expenses history spans 6 years, with the latest figure at $322743.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 36.08% year-over-year to $322743.0; the TTM value through Dec 2025 reached $322743.0, up 36.08%, while the annual FY2025 figure was $322743.0, 36.08% up from the prior year.
  • Other Accumulated Expenses reached $322743.0 in Q4 2025 per SABSW's latest filing, down from $649957.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $808363.0 in Q2 2025 to a low of $64850.0 in Q2 2024.
  • Average Other Accumulated Expenses over 5 years is $378896.8, with a median of $324827.0 recorded in 2024.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 76.29% in 2024, then soared 1146.51% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $283909.0 in 2021, then skyrocketed by 80.73% to $513110.0 in 2022, then fell by 28.97% to $364478.0 in 2023, then tumbled by 34.93% to $237164.0 in 2024, then surged by 36.08% to $322743.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Other Accumulated Expenses are $322743.0 (Q4 2025), $649957.0 (Q3 2025), and $808363.0 (Q2 2025).